search
pharmaceutical companies
Trends
- 1Kobayashi Pharmaceutical weighs buyout offer worth over ¥500 billion●Kobayashi Pharmaceutical, the firm that was at the center of a supplement contamination scandal involving suspected deat
Kobayashi Pharmaceutical, the Japanese company at the center of a supplement contamination scandal involving suspected deaths, is reportedly considering a buyout offer valued at more than ¥500 billion. The potential deal comes as the firm continues to face fallout from the scandal, which damaged consumer trust and hit its business hard. Market watchers are closely following how the offer could reshape the company's future.
- 2European Capital Backs Colombian Biotech Firm for 250 Million Vaccines▼Europe Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccines
European investors are injecting capital into a Colombian biotechnology company with plans to produce 250 million vaccines. The deal positions Colombia as a growing player in global vaccine manufacturing and reflects Europe's interest in diversifying pharmaceutical production capacity beyond its borders, though details on the funding amount and timeline remain limited.
- 3WSJ warns U.S. tariffs are hurting American biotech●The U.S. Tariff Attack on U.S. Biotech https://www.wsj.com/opinion/the-u-s-tariff-attack-on-u-s-biotech-c3406b92?mod=rss
The Wall Street Journal's opinion section argues that U.S. tariff policy is damaging the domestic biotechnology industry, which the piece frames as an ironic case of Washington's trade measures attacking American companies. The article is being shared in economic and policy discussions, drawing attention to the tension between protectionist trade policy and the administration's stated goal of strengthening U.S. industrial and pharmaceutical sectors.
- 4Meta paid ads promote Israeli settlement homes in West Bank●Meta runs paid ads promoting luxury homes in illegal Israeli settlements in the occupied West Bank. The same platform th
Meta is running paid advertisements promoting luxury homes in Israeli settlements in the occupied West Bank, according to reports circulating online. Critics point out the contradiction: the platform bans ads for counterfeit goods and unauthorized pharmaceuticals, yet accepts money from Israeli real estate companies marketing properties on Palestinian land. Settlements are considered illegal under international law, and the ads are drawing accusations that Meta is profiting from their promotion.
- 5
Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.
- 6Arrowhead Pharmaceuticals Stock Nears Five-Year High on Phase 3 Win▼ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval
Arrowhead Pharmaceuticals shares are on track to reach their highest level in more than five years after positive Phase 3 trial results, with retail investors celebrating the biotech's momentum. The company is reportedly aiming for a broader FDA approval than initially expected, fueling optimism about the commercial potential of its drug pipeline and driving renewed interest in the stock.
- 7Biosimilars Sector Poised for M&A Shake-Up as Patent Cliff Looms●Biosimilars at an Inflection Point: How Regulatory Reform, a Maturing Patent Framework and a Looming Patent Cliff Are Reshaping M&A
Legal and industry analysts say the biosimilars market has reached an inflection point, with regulatory reform, a maturing patent litigation framework and an approaching wave of major biologic patent expirations reshaping merger and acquisition strategy. Commentators expect pharmaceutical companies to pursue deals to capture market share as blockbuster biologics lose exclusivity and cheaper biosimilar competition intensifies.